Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model

Applied Health Economics and Health Policy

Volumn 16, Issue 6, 2018, Pages 889-899

  Prioli, Katherine M ^a   Karp, Julie Katz ^b   Lyons, Nina M ^c   Chrebtow, Vera ^d   Herman, Jay H ^b   Pizzi, Laura T ^a  

^a RUTGERS UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BLOOD SAMPLING; BUDGET; COMPARATIVE STUDY; FALSE POSITIVE RESULT; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; NONHUMAN; OUTPATIENT; PRIMARY CULTURE; RAPID BACTERIAL TESTING; REIMBURSEMENT; SEPSIS; SHELF LIFE; THROMBOCYTE; TRANSFUSION MEDICINE; ADVERSE EVENT; APHERESIS; BACTERIAL INFECTION; ECONOMICS; MICROBIOLOGY; PROCEDURES; STATISTICAL MODEL; THROMBOCYTE TRANSFUSION; UNITED STATES;

BACTERIAL INFECTIONS; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BLOOD SPECIMEN COLLECTION; BUDGETS; HOSPITAL COSTS; HUMANS; MODELS, ECONOMETRIC; PLATELET TRANSFUSION; UNITED STATES;

EID: 85050982980     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-018-0409-3     Document Type: Article

References (45)

1. Chung KW, Basavaraju SV, Mu Y, van Santen KL, Haass KA, Henry R, et al. Declining blood collection and utilization in the United States. Transfusion. 2016;56:2184–92
2. Mulcahy AW, Kapinos KA, Briscombe B, Uscher-Pines L, Chaturvedi R, Case SR, et al. Toward a sustainable blood supply in the United States: an analysis of the current system and alternatives for the future. Santa Monica: RAND Corporation; 2016
3. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. FDA draft guidance for industry, March 2016. https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm425952.pdf. Accessed 17 Feb 2017
4. Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion. 2013;53:1603–18
5. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion. 2010;50:589–99
6. Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang. 2008;95:13–9
7. Pearce S, Rowe GP, Field SP. Screening of platelets for bacterial contamination at the Welsh blood service. Transfus Med. 2011;21:25–32
8. Walther-Wenke G, Wirsing von Konig CH, Daubener W, Heiden M, Hoch J, Hornei B, Volkers P, Working Party on Bacteria Safety in Transfusion Medicine ABotGMoHB. Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang. 2011;100:359–66
9. Recommendations for donor screening, deferral, and product management to reduce the risk of transfusion-transmission of Zika Virus. FDA guidance for industry, August 2016. https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm518213.pdf. Accessed 28 Aug 2016
10. Anez G, Rios M. Dengue in the United States of America: a worsening scenario? Biomed Res Int. 2013;2013:678645
11. Petersen LR, Epstein JS. Chikungunya virus: new risk to transfusion safety in the Americas. Transfusion. 2014;54:1911–5
12. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl 2):1S–29S
13. Stein E, Elbadawi LI, Kazmierczak J, Davis JP. Babesiosis surveillance—Wisconsin, 2001–2015. MMWR Morb Mortal Wkly Rep. 2017;66:687–91
14. Stramer SL, Dodd RY, AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion. 2013;53(10 Pt 2):2375–83
15. Jacobs MR, Good CE, Lazarus HM, Yomtovian RA. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis. 2008;46(8):1214–20
16. Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127:496–502
17. Corean J, Al-Tigar R, Pysher T, Blaylock R, Metcalf RA. Quality improvement after multiple fatal transfusion-transmitted bacterial infections. Am J Clin Pathol. 2018;149(4):293–9
18. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply: time to raise the bar. N Engl J Med. 2015;372:1882–5
19. The INTERCEPT Blood System for Platelets Package Insert. Cerus Corporation; 2018. Available online at https://intercept-usa.com/images/resources/Package_Inserts/INTERCEPT_Blood_System_INT2530B_DS_Package_Insert_May-2018.pdf. Accessed 01 June 2018
20. Standards for Blood Banks and Transfusion Services. 30th ed. AABB; 2016. Available at https://marketplace.aabb.org/ebusiness/Default.aspx?TabID=251&productId=12991997. Accessed 27 Apr 2016
21. Platelet PGD Test Package Insert. Verax Biomedical; P00583 Rev. G,2015/06
22. Lyons NM, Prioli KM, Pizzi LT. Cost of platelet purchase and production: a survey of US Hospitals. Poster presentation at the 22nd annual international meeting of the international society for pharmacoeconomics and outcomes research; 20–24 May 2017: Boston, MA
23. Bureau of Labor Statistics (BLS). May 2015 National Occupational Employment and Wage Estimates. Available at https://www.bls.gov/oes/2015/may/oessrcst.htm. Accessed 15 Nov 2016
24. Employer costs for employee compensation. 2016. http://www.bls.gov/news.release/pdf/ecec.pdf. Accessed 15 Nov 2016
25. Prioli KM, Pizzi LT, Karp JK, Galanis T, Herman JH. Plasma cost focus group. cost of purchased versus produced plasma from donor recruitment through transfusion. Appl Health Econ Health Policy. 2016;14(5):609–17
26. National Blood Collection, Utilization, and Patient Blood Management Survey Report. AABB; 2013. Available at: http://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/2013-AABB-Blood-Survey-Report.pdf. Accessed 9 Jan 2017
27. McCullough J, Goldfinger D, Gorlin J, Riley WJ, Sandhu H, Stowell C, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion. 2015;55(10):2312–20
28. Kleinman S, Dumont LJ, Tomasulo P, Bianco C, Katz L, Benjamin RJ, et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion. 2009;49(5):903–12
29. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, Muncunill J, Serret C, Serra N, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion. 2014;54(1):158–68
30. Agency for Healthcare Research and Quality HCUPNet. Available at: http://hcupnet.ahrq.gov. Accessed 27 Nov 2016
31. SwissMedic haemovigilance annual reports, 2010–2015. Available at https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/haemovigilance/publications.html. Accessed 4 Jan 2017
32. Rapports d'activité hémovigilance/Hemovigilance Activity Reports, 2006-2015. Agence nationale de sécurité du médicament et des produits de santé/French National Agency for Medicine and Health Product Safety. Available at: http://ansm.sante.fr/Mediatheque/Publications/Bilans-Rapports-d-activite-Bilans-et-rapports-d-activite#folder_26762. Accessed 4 Jan 2017
33. Benjamin RJ, Braschler T, Weingand T, Corash LM. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion. 2017;57(12):2946–57
34. Hospital outpatient prospective payment: notice of final rulemaking (NFRM) with comment period. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1678-FC.html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending. Accessed 30 Nov 2017
35. Dunbar NM, Dumont LJ, Szczepiorkowski ZM. How do we implement day 6 and day 7 platelets at a hospital-based transfusion service? Transfusion. 2016;56:1262–6
36. Larson R, Aronson CA. Enhanced platelet bacterial screening in an eight-hospital system. AP52. AABB annual meeting; Oct 2017: San Diego, CA
37. Li JW, Brecher ME, Jacobson JL, Harm SK, Chen D, El-Gamil A, et al. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective. Transfusion. 2017;57:2321–8
38. Amato M, Schennach H, Astl M, Chen CY, Lin JS, Benjamin RJ, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang. 2017;112(1):47–55
39. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion. 2009;49:1412–22
40. Mendez B, McCable E, DelMonte J, Becker JL. The effects of PAS and PR on platelet use. CP311. Poster presentation at AABB; Oct 2017: San Diego, CA
41. Arefian H, Heublein S, Scherag A, Brunkhorst FM, Younis MZ, Moerer O, et al. Hospital-related cost of sepsis: a systematic review. J Infect. 2017;74:107–17
42. Jones SL, Ashton CM, Kiehne LB, Nicolas JC, Rose AL, Shirkey BA, et al. Outcomes and resource use of sepsis-associated stays by presence on admission, severity, and hospital type. Med Care. 2016;54(3):303–10
43. Navy wife who lost kidneys after giving birth awarded $24.7 M. https://www.usnews.com/news/best-states/hawaii/articles/2018-03-08/navy-wife-who-lost-kidneys-after-giving-birth-awarded-247m. Accessed 5 Mar 2018
44. FDA Blood Products Advisory Committee 2017. Meeting materials. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm543914.htm. Accessed 5 Mar 2018
45. National Blood Collection and Utilization in the United States (NBCUS) report. Presented at the AABB annual meeting; 22–25 Oct 2016: Orlando, FL